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Abstract
Background: Protracted low-dose concurrent chemotherapy combined with radiation has been
proposed for enhanced treatment results for esophageal cancer. We evaluated the efficacy and the
toxicity of a novel regimen of daily low-dose nedaplatin (cis-diammine-glycolatoplatinum) and
continuous infusion of 5-fluorouracil (5-FU) with radiation in patients with esophageal squamous
cell carcinoma.
Methods: Between January 2003 and June 2008, 33 patients with clinical stage I to IVB esophageal
squamous cell carcinoma were enrolled. Nedaplatin (10 mg/body/day) was administered daily and
5-FU (500 mg/body/day) was administered continuously for 20 days. Fractionated radiotherapy for
a total dose of 50.4-66 Gy was administered together with chemotherapy. Additional
chemotherapy with nedaplatin and 5-FU was optionally performed for a maximum of 5 courses
after chemoradiotherapy. The primary end-point of this study was to evaluate the tumor response,
and the secondary end-points were to evaluate the toxicity and the overall survival.
Results: Twenty-two patients (72.7%) completed the regimen of chemoradiotherapy. Twenty
patients (60.6%) achieved a complete response, 10 patients (30.3%) a partial response. One patient
(3.0%) had a stable disease, and 2 (6.1%) a progressive disease. The overall response rate was 90.9%
(95% confidence interval: 75.7%-98.1%). For grade 3-4 toxicity, leukopenia was observed in 75.8%
of the cases, thrombocytopenia in 24.2%, anemia in 9.1%, and esophagitis in 36.4%, while late grade
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BMC Cancer 2009, 9:408 http://www.biomedcentral.com/1471-2407/9/4083-4 cardiac toxicity occurred in 6.1%. Additional chemotherapy was performed for 26 patients
(78.8%) and the median number of courses was 3 (range, 1-5). The 1-, 2- and 3-year survival rates
were 83.9%, 76.0% and 58.8%, respectively. The 1- and 2-year survival rates were 94.7% and 88.4%
in patients with T1-3 M0 disease, and 66.2% and 55.2% in patients with T4/M1 disease.
Conclusion: The treatment used in our study may yield a high complete response rate and better
survival for each stage of esophageal squamous cell carcinoma.
Trial registration: ClinicalTrials.gov Identifier: NCT00197444
Background
Results of a series of clinical trials indicate that definitive
chemoradiotherapy (CRT) for esophageal cancer pro-
duces more promising results than radiation therapy
alone, and is considered to be the standard treatment for
patients with medically inoperable or surgically unresect-
able esophageal cancer [1-3]. Recently reported results
obtained with this treatment indicate it can provide sur-
vival benefits comparable to those in the Western series of
surgery alone, and is one of the standard treatments, even
for resectable-stage disease [4]. In Japan, where squamous
cell carcinoma is dominant in esophageal cancer, the use
of CRT rather than surgery is spreading, thus making it
desirable to establish a more effective CRT protocol to
achieve a complete response rate and improved survival.
It is also necessary to investigate which anticancer drugs
are more efficacious and how to best use these drugs in
combination with radiation for better complete response
rates and survival [5].
Nedaplatin (cis-diammine-glycolatoplatinum: CDGP) is
a second-generation platinum complex that was devel-
oped to reduce nephrotoxicity and maintain the effective-
ness of cisplatin [6-8]. Numerous single agents have been
tested for the treatment of esophageal cancer and the over-
all response rate has typically ranged from 15%-30%
[9,10], whereas the response rate for nedaplatin as a single
agent was 51.7% with little toxicity in a phase II study
[11]. Recently, phase I and II studies of chemoradiother-
apy using intermittent standard-dose nedaplatin with 5-
fluorouracil (FU) for esophageal squamous cell carci-
noma were performed and demonstrated the safety and
efficacy of this treatment [12-14].
Protracted low-dose concurrent chemotherapy combined
with radiation has been proposed for more satisfactory
local control rates without severe systemic toxic effects
[15,16]. Platinum is not only a cytotoxic agent, but also a
chemical modulator and radiosensitizer that enhances the
chemotherapeutic effects of 5-FU on tumor cells [17-19].
Therefore, daily low-dose nedaplatin and 5-FU combined
with radiation may be a more effective regimen than the
previously reported intermittent standard-dose regimen.
In this study, we prospectively evaluated the efficacy and
the toxicity of a regimen of daily low-dose nedaplatin and
continuous infusion of 5-FU combined with radiation in
patients with esophageal squamous cell carcinoma at an
institution in Japan.
Methods
Patients and pre-treatment evaluation
Between January 2003 and June 2008, 33 patients with
histologically proven squamous cell carcinoma of the
esophagus were enrolled and treated in accordance with
our protocol. Eligibility criteria were: Eastern Cooperative
Oncology Group performance status 0-2; age <85 years;
white blood cells >3 × 103/μl; platelets >1 × 105/μl; serum
total bilirubin <2.0 mg/dl; serum transaminase <3 times
the upper normal limit; serum creatinine <1.5 mg/dl; cre-
atinine clearance ≥ 60 ml/min; no serious cardiac disease;
no prior chemotherapy or radiotherapy and receipt of
informed consent.
The tumor stages were classified according to the TNM
classification (sixth edition) of the International Union
against Cancer (UICC). Tumor stages were conventionally
determined by means of computed tomography (CT) or
magnetic resonance imaging (MRI) of the neck, chest and
abdomen, endoscopy and esophagography. Endoscopic
ultrasonography was performed to determine the tumor
invasion within the esophageal wall for the patients with
suspected Stage I disease. As a rule, patients with disease
limited to the mucosal layer and those with metastasis to
distant organs were excluded from this study, but patients
who had distant lymph node metastasis that could be
encompassed in a single radiation field were included
[M1 lymph node metastasis (M1 lym)].
Treatment
Low-dose nedaplatin (10 mg/body/day) was adminis-
tered daily for 20 days on days 1-5, 8-13, 15-19 and 22-26,
and 5-FU (500 mg/body/day) was continuously adminis-
tered for 20 days on days 1-5, 8-13, 15-19 and 22-26. A
serotonin receptor antagonist was preventively given as an
antinauseant just before the administration of nedaplatin.Page 2 of 10
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source for the external radiotherapy. Positioning of the
fields and dosimetry were studied using a CT scan and 3D
treatment planning. The treatment fields encompassed
the tumor bed with 3-5 cm proximal and distal margins
and 1 cm lateral margins. Supraclavicular nodes were
included in the treatment portals for the upper and the
middle thoracic tumors; celiac nodes were included for
the lower and the middle thoracic tumors. Fractionated
external radiotherapy was performed from the first day of
chemotherapy, administrated 5 days a week, and a total
dose of 50.4-66 Gy was delivered at a rate of 1.8-2.0 Gy
per fraction to all but two patients. After a dose of 40 Gy,
the field was changed for all but two patients to avoid the
spinal cord irradiation, and only macroscopic lesions
were irradiated with a margin of at least 1 cm. Two
patients with stage I disease and diagnosed before March
2005 were given 12 Gy/3 fractions of high-dose-rate intra-
luminal brachytherapy (HDRIBT) after 40 Gy of external
irradiation. HDRIBT was performed at a level 5 mm below
the surface of the mucosa with a margin of at least 2 cm by
remote after loading system every 3-4 days; the total
planned dose of external and intraluminal irradiation was
52 Gy. Dose variation of radiation therapy among the
enrolled patients was presented in Table 1.
Chemotherapy interruption criteria were: white blood cell
count <2 × 103/mm3; platelet count <5 × 104/mm3; body
temperature of 38°C or more and any other life-threaten-
ing toxicities. Irradiation interruption criteria were a white
blood cell count of <1.5 × 103/mm3 and any other life-
threatening toxicities. The study protocol was approved in
advance by the Human Institutional Review Boards of
Hamamatsu University School of Medicine and was regis-
tered as ClinicalTrials.gov Identifier: NCT00197444. Writ-
ten informed consent was obtained from all patients
before starting treatment. This study was conducted to
conform to the principles of the Declaration of Helsinki.
For patients who showed an objective response to the
treatment, additional chemotherapy was optionally per-
formed using 14 mg/m2/day nedaplatin and continuous
infusion of 500 mg/m2/day 5-FU on days 1-5. This chem-
otherapy was repeated every 4 weeks for a maximum of 5
courses, after which no further treatment was performed if
a complete response was obtained.
Evaluations of response and toxicity
The primary end-point of this study was to evaluate the
tumor response, the response rate (RR) and the complete
response (CR) rate. The secondary end-points were to
evaluate the toxicity and the overall survival. Follow-up
evaluations were performed by endoscopy with biopsy,
and CT and/or MRI of the neck, chest and abdomen, every
3 months for the first year and every 6 months thereafter.
All the follow-up data were updated at the end of Decem-
ber 2008. Tumor response was assessed according to the
Response Evaluation Criteria in Solid Tumors (RECIST)
(UICC, 2002) and initially evaluated within 1 month after
chemoradiotherapy. RECIST does not refer to CR criteria
for primary lesions by endoscopy in detail, and endo-
scopic methods of evaluation have not yet been fully val-
idated. In this study, CR for the primary tumor was
defined by endoscopy when all visible tumors, including
ulceration, disappeared with negative biopsy and lasted
for ≥ 4 weeks according to the previous studies [20,21].
Confirmation of CR and PR were usually evaluated 3
months after initial evaluation. Toxicities were graded
according to the Common Terminology Criteria for
Adverse Events v3.0. All of the early hematologic toxicities
were defined to be related with chemoradiotherapy and
observed before additional chemotherapy.
Statistical analysis
Statistical differences in tumor response rates between the
2 groups were determined by Fisher's exact test. The Kap-
lan-Meier method was used for survival calculations based
on the first day of chemoradiotherapy, and the log-rank
test for comparisons between groups. All p-values were
two-sided, and a level of p < 0.05 was considered to be sta-
tistically significant. All statistical analyses were per-
formed using the StatView software for Windows, Version
5.0 (SAS Institute, Cary, NC, USA).
Results
Patient characteristics
The demographic clinical characteristics of the 33 patients
are presented in Table 2. The median age was 66.0 years
(range, 55-82 years). Most of the patients had tolerable
performance status for the treatment; the performance sta-
tus was 0, 1 and 2 in 6, 21 and 6 patients, respectively.
According to TNM classification, there were 7, 3, 12 and
11 patients with T1, T2, T3 and T4 disease, respectively.
Lymph node metastasis was observed in 23 patients.
Among these patients, there were 6 patients with M1 lym.
Nineteen patients had T1-3 M0 diseases that were in
resectable stages, whereas 14 patients had T4 and/or M1
lym disease. The median follow-up period for all patients
Table 1: Variations of initial irradiation dose
Radiation therapy Dose variation Patients
External and intraluminal 40 Gy + 12 Gy 2*
External 50.4 Gy 2
60 Gy 19
66 Gy 8
*, who were diagnosed as clinical Stage I (T1N0 M0)Page 3 of 10
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to follow-up.
Response to therapy
For the initial response, 20 of the 33 patients achieved a
complete response (CR), 10 had a partial response (PR), 1
had stable disease (SD) and 2 had progressive disease
(PD). The overall response rate (CR + PR) was 90.9%
(95% confidence interval [CI] = 75.7%-98.1%). The CR
rate for T1-3 M0 disease was significantly higher than for
T4/M1 disease (84.2% versus 28.6%; p = 0.0031), while
no statistical significance was observed for the response
rate (CR + PR). The CR rate was significantly higher in the
absence than in the presence of lymph node metastasis
(90.0% versus 47.8%, p = 0.0495), while again no statisti-
cal significance was observed in the response rate (Table
3).
Survival rate
Thirteen patients had died by the end of follow-up. Sal-
vage surgery after recurrence was not performed in any of
the patients in this series. The overall survival rates at 1, 2
and 3 years were 83.9% (95% CI = 71.0%-96.8%), 76.0%
(95% CI = 60.3%-91.7%) and 58.8% (95% CI = 37.8%-
79.8%). respectively. Median survival time (MST) was
39.0 months (95% CI = 29.5%-48.5%) (Figure 1A). We
compared the survival rates of the 19 patients with T1-3
M0 disease with those of the 14 patients with T4/M1 dis-
ease. The 1- and 2-year survival rates were 94.7% (95% CI
= 84.7%-100.0%) and 88.4% (95% CI = 73.2%-100.0%)
respectively, in patients with T1-3 M0 disease and were
66.2% (95% CI = 38.8%-93.6%) and 55.2% (95% CI =
25.0%-85.4%) respectively, in patients with T4/M1 dis-
ease. The survival rates between T1-3 M0 and T4/M1
patients were significantly different (p = 0.032) (Figure
1B). A comparison of the survival rates of 10 patients
without lymph node metastasis with those of 23 patients
with lymph node metastasis also showed a significant dif-
ference (p = 0.025) (Figure 1C). The 1- and 2-year survival
rates for patients without lymph node metastasis were
both 100%, and for those with lymph node metastasis
they were 76.7% (95% CI = 58.9%-94.5%) and 66.1%
(95% CI = 45.5%-86.7%), respectively.
Toxicity
The toxicity grades detected in this study are shown in
Table 4. Grade 3-4 leukopenia was observed in 25 patients
(75.8%) and grade 3-4 thrombocytopenia in 8 patients
(24.2%). As for non-hematological toxicity, grade 3-4
esophagitis was found in 12 patients (36.4%). As for late
toxicity, grade 3-4 pericarditis was detected in 2 patients
and grade 3 pleuritis in 1 patient. No treatment-related
deaths occurred in this study.
Effect of protocol completion or additional chemotherapy 
on survival rate
Nine patients (27.3%) did not complete the regimen of
chemoradiotherapy because of adverse events in the acute
phase. Among these, one patient did not complete both of
the radiation therapy (at the dose of 36 Gy) and chemo-
therapy due to severe bone marrow suppression and
febrile condition. Another patient did not complete the
radiation therapy at the dose of 46 Gy due to the Grade 3
leukopenia and patient's refusal of the continuation of
therapy due to depressive mental condition. The other 7
patients could not continue the chemotherapy suffered
Table 2: Patient characteristics
No. of patients 33
Male/Female 25/8
Age, years: median (range) 66 (55--82)
Performance status (ECOG)
0/1/2 6/21/6
Stage (UICC 1997)
I* 6
IIA/B 3/3
III 15
IVA/B 3/3
TNM clinical classification (UICC 1997)
T1/T2/T3/T4 7/3/12/11
N0/N1 10/23
M0/M1 lym 27/6
Pathology
Well/Mod/Poor 4/25/4
Location
Upper/Middle/Lower 3/19/11
ECOG, Eastern Cooperative Oncology Group; UICC, International 
Union Against Cancer; M1 lym, M1 lymph node metastasis; Well, 
well-differentiated squamous carcinoma; Mod, moderately-
differentiated squamous carcinoma; Poor, poorly-differentiated 
squamous carcinoma
*: disease with submucosal invasion
Table 3: Response results
Category Total No. CR PR SD PD RR (%)
Overall 33 20 10 1 2 90.9
T1-3 M0 19 16 3 0 0 100
T4/M1 14 4 7 1 2 78.6
N0 10 9 1 0 0 100
N1 23 11 9 1 2 87.0
CR, complete response; PR, partial response; SD, stable disease; PD, 
progressive disease; RR, response ratePage 4 of 10
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Survival rate calculated by the Kaplan-Meier methodFigure 1
Survival rate calculated by the Kaplan-Meier method. (A) Overall survival among all patients. (B) Comparison between 
T1-3 M0 and T4/M1 groups. (C) Comparison between groups of patients with and without lymph node metastasis.
BMC Cancer 2009, 9:408 http://www.biomedcentral.com/1471-2407/9/408from hematological toxicities. We examined whether the
protocol completion affected the survival rates. There was
no statistically significant difference in survival rates
between those who completed chemoradiotherapy and
those who did not (Figure 2A).
In the present study, additional optional chemotherapy
with nedaplatin and 5-FU, repeated every 4 weeks for a
maximum of 5 courses, was performed for patients show-
ing an objective response to the treatment. Additional
chemotherapy was performed for 26 patients (78.8%),
and the median number of courses was 3 (range, 1-5).
Although the number of patients was small and the fol-
low-up period was relatively short in this series, there was
no statistically significant difference in survival rate
between the patients who received additional adjuvant
chemotherapy and those who did not (Figure 2B).
Discussion
Protracted low-dose concurrent chemotherapy combined
with radiation is one of the methods which have been
proposed for improve tumor response and survival of
esophageal cancer patients [5]. In this study, we prospec-
tively evaluated the efficacy and toxicity of a regimen of
daily low-dose nedaplatin, a second-generation platinum,
and continuous infusion of 5-FU combined with radia-
tion in patients with esophageal squamous cell carcinoma
at an institution in Japan. The overall response rate
(90.9%) and MST (39.0 months) for this treatment were
relatively high compared with other chemoradiotherapy
regimens for esophageal cancer. The 1- and 2-year survival
rates were 94.7% and 88.4%, respectively, in patients with
T1-3 M0 disease and 66.2% and 55.2%, respectively, in
patients with T4/M1 disease. The treatment used in our
study can thus be expected to yield superior survival rates
for every stage of esophageal squamous cell carcinoma.
Since the Radiation Therapy Oncology Group (RTOG)
phase III trial (RTOG 85-01) and the inter-group phase III
trial, concurrent chemoradiotherapy using 5-FU and cispl-
atin has been considered the standard treatment for
locally advanced esophageal cancer [1,3,22]. For this ther-
apy, the chemotherapy agents are administered intermit-
tently. According to previous clinical trials of this type of
chemoradiotherapy for esophageal squamous cell carci-
noma, T1N0 M0 patients showed 3- and 5-year overall
survival rates of 80% and 75.5%-77%, respectively, while
the corresponding rates in T2-3/M0 patients were 49%
and 46%, with a MST of 34 months [23]. In T4/M1
patients, 3- and 5-year overall survival rates 22%-23% and
13%-17%, with a MST of 9-10 months [21,24]. This type
of chemotherapy regimen is characterized by a significant
incidence of high-grade acute gastrointestinal and renal
toxicity.
Low-dose protracted infusion chemotherapy combined
with radiotherapy has been used for several cancers in the
hope of attaining a longer radiosensitizing effect without
severe toxicity, and positive results have been reported
[25-27]. However, only a few studies have been con-
ducted of low-dose protracted infusion chemotherapy
combined with radiotherapy for oesophageal cancer [28-
30]. A recent randomized phase II study of esophageal
cancer by the Japanese Radiation Oncology Study Group,
which used protracted low-dose cisplatin and continuous
5-FU infusion, did not indicate any superiority of survival
over standard intermittent chemotherapy combined with
radiation [30]. In the study presented here, we used neda-
platin, which is reportedly a more effective anticancer
drug for oesophageal cancer when used alone, for reduc-
ing gastrointestinal and renal toxicity. Details of previous
clinical studies of chemoradiotherapy using nedaplatin
and 5-FU for esophageal cancer are shown in Table 5. For
definitive chemoradiotherapy using intermittent stand-
ard-dose nedaplatin and 5-FU regimens, the CR rate was
reported to be 9%-73% with 1- and 2-year survival rates of
30.7%-65.1% and 10.2%-45.9%, respectively. Compared
to the intermittent standard-dose nedaplatin and 5-FU
regimens, the daily low-dose nedaplatin and 5-FU regi-
men seems to yield relatively high CR and survival rates.
However, leukopenia was also frequently observed in
patients receiving the daily low-dose regimen, even
though the total drug doses were almost the same.
Esophageal cancer surgery is still the standard treatment
for resectable stages. Recent studies have shown that neoa-
juvant chemotherapy or chemoradiotherapy with surgery
can provide survival advantages for locally advanced
esophageal cancer [31,32]. However, recovery of health-
related quality of life with surgery is reportedly signifi-
Table 4: Toxicities
Grade
Toxicity 0 1 2 3 4 Grade ≥3
(%)
~Early toxicity~
Leukopenia 0 1 7 21 4 75.8
Thrombocytopenia 1 13 11 8 0 24.2
Anemia 3 15 12 2 1 9.1
Renal dysfunction 32 1 0 0 0 0
Transaminase 33 0 0 0 0 0
Esophagitis 1 11 9 12 0 36.4
Nausea/Vomiting 17 11 5 0 0 0
Mucositis 23 5 3 2 0 6.1
~Late Toxicity~
Pericarditis 24 6 1 1 1 6.1
Pneumonitis 11 21 0 0 0 0
Pleuritis 24 8 0 1 0 3.0
Esophageal stricture 27 0 1 5 0 15.2
Bone fracture 32 0 1 0 0 0Page 6 of 10
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diotherapy [33,34], since the latter has the absolute
advantage of conserving the esophagus and stomach. A
certain number of patients are therefore likely to choose
this treatment until a more effective methodology is
developed.
Although previous studies of intermittent standard-dose
chemoradiotherapy using cisplatin and 5-FU reported 2-
10% treatment related death [3,22], no treatment-related
death occurred in our study in spite of frequent early
hematological toxicity. One of the advantages of pro-
tracted low-dose concurrent chemotherapy combined
with radiation is that we could discontinue the chemo-
therapy when severe adverse effects such as bone marrow
suppression were observed during the treatment, and we
could also restrict the total doses of anticancer drugs to
minimize these adverse effects. Our results show that fail-
ure to complete the protocol was not associated with sur-
vival, but may have contributed to the absence of
treatment-related death. Long-term cardiac toxicity and
pleural effusion after CRT for esophageal cancer are signif-
icant problems for quality of life and future survival. Dur-
ing our treatment, the frequency of pericarditis and/or
pleuritis seemed to be similar to that in previously
reported studies using intermittent standard-dose cispla-
tin and 5-FU [35,36].
Although the protocol of this study had not any restriction
of the salvage surgery for locoregional recurrence and we
were always worth considering the salvage surgery after
recurrence, there was no patient in this series who was
able to tolerate to and agree to the salvage surgery due to
circumstances. Therefore, all of the patients who had loco-
regional recurrence were treated with chemotherapy in
this series. If the salvage surgery would be more safe treat-
ment option for the high risk patients and its indication
would be expanded, further improvement of survival shall
be expected.
There are several limitations to this study. We allowed the
dose of radiation to vary from 50.4-66 Gy and also admin-
istered intraluminal brachytherapy after 40 Gy of external
irradiation in 2 patients. These variations may have
affected the response or survival rates, although the RTOG
94-05 trial made it clear that higher radiation doses (64.8
Gy) could not improve locoregional control compared to
that obtained with 50.4 Gy [22]. We also permitted
optional additional chemotherapy that could be repeated
for a maximum of 5 courses after chemoradiotherapy. We
performed a subgroup analysis for patients treated with
adjuvant chemotherapy, which confirmed there was no
statistically significant advantage in the survival curve.
However, we may not conclude that our results com-
pletely deny the value of adjuvant chemotherapy, since
the number of patients was small and follow-up period
may not be sufficient.
Because of the relatively small number of patients in our
study, further clinical studies are required with a larger
number of patients and in a multicenter setting to confirm
whether daily low-dose nedaplatin and continuous infu-
sion of 5-FU combined with radiation is an effective alter-
native to the conventional or modified RTOG 85-01
regimen using intermittent standard doses of cisplatin
and 5-FU. Nevertheless, our results indicate that the
former may provide a higher CR rate and survival for
The effects of treatment completion or additional adjuvant c emotherapy on survival rateFigure 2
The effects of treatment completion or additional 
adjuvant chemotherapy on survival rate. (A) Compari-
son between groups that did and groups that did not com-
plete the treatment. (B) Comparison between groups with 
or without additional chemotherapy after the initial chemo-
radiotherapy. CT, chemotherapy.Page 7 of 10
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believe this regimen is a promising candidate meriting a
phase III trial to determine whether it can become the
standard regimen for esophageal squamous cell carci-
noma.
Conclusion
Daily low-dose nedaplatin and continuous 5-FU infusion
combined with radiation may yield a higher CR rate and
better survival for patients with esophageal squamous cell
carcinoma.
Abbreviations
CDGP: cis-diammine-glycolatoplatinum (nedaplatin); 5-
FU: 5-fluorouracil; CRT: chemoradiotherapy; UICC: Inter-
national Union against Cancer; CT: computed tomogra-
phy; MRI: magnetic resonance imaging; M1 lym: M1
lymph node metastasis; HDRIBT: high-dose-rate intralu-
Table 5: Comparison among chemoradiotherapy studies, using nedaplatin/5-FU for esophageal cancer
A. Daily low-dose nedaplatin and 5-FU regimens
Author No. Radiation
(Gy)
Total dose (mg)
Nedaplatin
5-FU
Stage RR
(%)
CR
(%)
Survival rate (%) Leucopenia (%)
Inaba H
[37]
10 60 200/body
10,000/body
I--IVB 80 50 80 (1 y) 90
Osawa S * 33 50.4--66 200/body
10,000/body
I--IVB 90.9 60.6 83 (1 y)
77 (2 y)
75.8
B. Intermittent standard-dose nedaplatin and 5-FU regimens
Author No. Radiation
(Gy)
Total dose (mg)
Nedaplatin
5FU
Stage RR
(%)
CR
(%)
Survival rate (%) Leucopenia (%)
Kato H
[38]
22 60--66 160/m2
5,000/m2
I--IV 77 9 30.7 (1 y)
10.2 (2 y)
15.4
17 40 80/m2
25,000/m2
pre-S
II--IV
70.6 28.6 48.2 (1 y)
12.1 (2 y)
Yamanaka H
[39]
17 40 200/body
14,000/body
I--IVB 76.5 11.8 52.9 (1 y) 17.6
Nemoto K
[40]
17 60--70 200/body
15,000/body
I--IVA 94.1 41.2 59 (1 y)
39 (2 y)
25
7 60--70 200/body
15,000/body
post-S
recur
100 0 69 (1 y)
69 (2 y)
Ishikura S
[14]
26 60 180/m2
8,000/m2
III--IVB --- 12 50 (1 y)
31 (2 y)
35
Sato Y
[12]
26 60 100/m2
4,000/m2
I--IVA 88.5 42.3 65.1 (1 y)
37.2 (3 y)
40
Kodaira T
[13]
40 60 360/m2
10,500/m2
III--IV 76 48 58.9 (1 y)
45.9 (2 y)
80
Yamashita H
[41]
12 50.4 160/m2
6,400/m2
II--IVB 82 73 40 (1 y)
13 (2 y)
50
Jingu K
[42]
30 60 140/m2
5,000/m2
post-S
recur
73.3 13.3 60.6 (1 y)
56.3 (3 y)
30
*, present study; RR, response rate; CR, complete response; pre-S, pre-surgical; post-S recur, post-surgical recurrence; 1 y, 1-year; 2 y, 2-yearPage 8 of 10
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Median survival time; RTOG: Radiation Therapy Oncol-
ogy Group.
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